User menu

Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis

Bibliographic reference McEneny-King, Alanna ; Chelle, Pierre ; Henrard, Séverine ; Hermans, Cédric ; Iorio, Alfonso ; et. al. Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis. In: Pharmaceutics, Vol. 9, p. 47 (2017)
Permanent URL
  1. Den UIJL I. E. M., MAUSER BUNSCHOTEN E. P., ROOSENDAAL G., SCHUTGENS R. E. G., BIESMA D. H., GROBBEE D. E., FISCHER K., Clinical severity of haemophilia A: does the classification of the 1950s still stand? : CLASSIFICATION IN HAEMOPHILIA, 10.1111/j.1365-2516.2011.02539.x
  2. Manco-Johnson Marilyn J., Abshire Thomas C., Shapiro Amy D., Riske Brenda, Hacker Michele R., Kilcoyne Ray, Ingram J. David, Manco-Johnson Michael L., Funk Sharon, Jacobson Linda, Valentino Leonard A., Hoots W. Keith, Buchanan George R., DiMichele Donna, Recht Michael, Brown Deborah, Leissinger Cindy, Bleak Shirley, Cohen Alan, Mathew Prasad, Matsunaga Alison, Medeiros Desiree, Nugent Diane, Thomas Gregory A., Thompson Alexis A., McRedmond Kevin, Soucie J. Michael, Austin Harlan, Evatt Bruce L., Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia, 10.1056/nejmoa067659
  3. Fischer K., Collins P. W., Ozelo M. C., Srivastava A., Young G., Blanchette V. S., When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH, 10.1111/jth.13298
  4. Berntorp Erik, Spotts Gerald, Patrone Lisa, Ewenstein Bruce, Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method, 10.2147/btt.s53456
  5. PETRINI P., Identifying and overcoming barriers to prophylaxis in the management of haemophilia, 10.1111/j.1365-2516.2007.01501.x
  6. Oldenburg J., Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens, 10.1182/blood-2015-01-528414
  7. Björkman Sven, Folkesson Anna, Jönsson Siv, Pharmacokinetics and dose requirements of factor VIII over the age range 3–74 years : A population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A, 10.1007/s00228-009-0676-x
  8. CARLSSON M., BERNTORP E., BJORKMAN S., LETHAGEN S., LJUNG R., Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A, 10.1046/j.1365-2516.1997.00091.x
  9. Iorio Alfonso, Keepanasseril Arun, Foster Gary, Navarro-Ruan Tamara, McEneny-King Alanna, Edginton Andrea N, Thabane Lehana, Development of a Web-Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS-Hemo): Study Protocol, 10.2196/resprot.6558
  10. McEneny-King Alanna, Foster Gary, Iorio Alfonso, Edginton Andrea N, Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo), 10.2196/resprot.6559
  11. Ingram G. I. C., CALCULATING THE DOSE OF FACTOR VIII IN THE MANAGEMENT OF HAEMOPHILIA, 10.1111/j.1365-2141.1981.tb02722.x
  12. Poon Man-Chiu, Lee Adrienne, Individualized prophylaxis for optimizing hemophilia care: can we apply this to both developed and developing nations?, 10.1186/s12959-016-0096-y
  13. Ullman M., Zhang Q. C., Brown D., Grant A., Soucie J. M., , Association of overweight and obesity with the use of self and home-based infusion therapy among haemophilic men, 10.1111/hae.12303
  14. REVEL-VILK S., KOMVILAISAK P., BLANCHETTE V., STAIN A. M., FLOROS G., COCHRANE A., BLANCHETTE C., HANG M., ROBERTS E. A., LING S. C., The changing face of hepatitis in boys with haemophilia associated with increased prevalence of obesity : HEPATITIS AND OBESITY IN HAEMOPHILIA, 10.1111/j.1365-2516.2010.02477.x
  15. Young, Hematol. Am. Soc. Hematol. Educ. Program., 2012, 362 (2012)
  16. Shapiro A. D., Korth-Bradley J., Poon M.-C., Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia, 10.1111/j.1365-2516.2005.01149.x
  17. Henrard S., Speybroeck N., Hermans C., Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients, 10.3324/haematol.2013.084038
  18. McLeay Sarah C., Morrish Glynn A., Kirkpatrick Carl M.J., Green Bruce, The Relationship between Drug Clearance and Body Size : Systematic Review and Meta-Analysis of the Literature Published from 2000 to 2007, 10.2165/11598930-000000000-00000
  19. Cheymol Georges, Effects of Obesity on Pharmacokinetics : Implications for Drug Therapy, 10.2165/00003088-200039030-00004
  20. Hanley Michael J., Abernethy Darrell R., Greenblatt David J., Effect of Obesity on the Pharmacokinetics of Drugs in Humans : , 10.2165/11318100-000000000-00000
  21. Bjorkman S., Oh M., Spotts G., Schroth P., Fritsch S., Ewenstein B. M., Casey K., Fischer K., Blanchette V. S., Collins P. W., Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight, 10.1182/blood-2011-07-360594
  22. Kawai Ryosei, Lemaire Michel, Steimer Jean-Louis, Bruelisauer Armin, Niederberger Werner, Rowland Malcolm, Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125, 10.1007/bf02353860
  23. Tuinenburg A., Biere-Rafi S., Peters M., Verhamme P., Peerlinck K., Kruip M. J. H. A., Laros-Van Gorkom B. A. P., Roest M., Meijers J. C. M., Kamphuisen P. W., Schutgens R. E. G., Obesity in haemophilia patients: effect on bleeding frequency, clotting factor concentrate usage, and haemostatic and fibrinolytic parameters, 10.1111/hae.12182
  24. Taylor BreAnn N., Bork Sara J.D., Kim Shelly, Moffett Brady S., Yee Donald L., Evaluation of Weight-Based Dosing of Unfractionated Heparin in Obese Children, 10.1016/j.jpeds.2012.12.095
  25. RISEBROUGH N., OH P., BLANCHETTE V., CURTIN J., HITZLER J., FELDMAN B. M., Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A, 10.1111/j.1365-2516.2008.01664.x
  26. Johnson K. A., Zhou Z.-Y., Costs of Care in Hemophilia and Possible Implications of Health Care Reform, 10.1182/asheducation-2011.1.413
  27. MAJUMDAR S., OSTRENGA A., LATZMAN R. D., PAYNE C., HUNT Q., MORRIS A., IYER R., Pharmacoeconomic impact of obesity in severe haemophilia children on clotting factor prophylaxis in a single institution : LETTERS TO THE EDITOR, 10.1111/j.1365-2516.2010.02462.x
  28. Fryar, Vital Health Stat. 3, 39, 1 (2016)
  29. Janmahasatian Sarayut, Duffull Stephen B, Ash Susan, Ward Leigh C, Byrne Nuala M, Green Bruce, Quantification of Lean Bodyweight : , 10.2165/00003088-200544100-00004
  30. Green Bruce, Duffull Stephen B., What is the best size descriptor to use for pharmacokinetic studies in the obese?, 10.1111/j.1365-2125.2004.02157.x
  31. Garmann D., McLeay S., Shah A., Vis P., Maas Enriquez M., Ploeger B.A., Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit, 10.1111/hae.13192
  32. COLLINS P. W., BLANCHETTE V. S., FISCHER K., BJÖRKMAN S., OH M., FRITSCH S., SCHROTH P., SPOTTS G., ASTERMARK J., EWENSTEIN B., , Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A, 10.1111/j.1538-7836.2008.03270.x
  33. COLLINS P., FARADJI A., MORFINI M., ENRIQUEZ M. M., SCHWARTZ L., Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study, 10.1111/j.1538-7836.2009.03650.x
  34. COLLINS P. W., FISCHER K., MORFINI M., BLANCHETTE V. S., BJÖRKMAN S., , Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia : PHARMACOKINETICS AND PROPHYLAXIS, 10.1111/j.1365-2516.2010.02370.x
  35. Richards Michael, Williams Michael, Chalmers Elizabeth, Liesner Ri, Collins Peter, Vidler Vicky, Hanley John, A United Kingdom Haemophilia Centre Doctors’ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A : Guideline, 10.1111/j.1365-2141.2010.08139.x
  36. Shapiro A. D., Long-lasting recombinant factor VIII proteins for hemophilia A, 10.1182/asheducation-2013.1.37
  37. Barrowcliffe T. W., Monitoring haemophilia severity and treatment: new or old laboratory tests?, 10.1111/j.1365-2516.2004.00985.x
  38. COLLINS P. W., BJÖRKMAN S., FISCHER K., BLANCHETTE V., OH M., SCHROTH P., FRITSCH S., CASEY K., SPOTTS G., EWENSTEIN B. M., Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens, 10.1111/j.1538-7836.2009.03703.x
  39. Ljung Rolf, Aspects of prophylactic treatment of hemophilia, 10.1186/s12959-016-0103-3
  40. Jackson Shannon C, Yang Ming, Minuk Leonard, Sholzberg Michelle, St-Louis Jean, Iorio Alfonso, Card Robert, Poon Man-Chiu, Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions, 10.1186/s12878-015-0022-8
  41. Oldenburg Johannes, Brackmann Hans-Hermann, Prophylaxis in adult patients with severe haemophilia A, 10.1016/j.thromres.2013.10.019
  42. Graham A., Jaworski K., Pharmacokinetic analysis of anti-hemophilic factor in the obese patient, 10.1111/hae.12300
  43. KOMWILAISAK P., BLANCHETTE V., Pharmacokinetic studies of coagulation factors: relevance of plasma and extracellular volume and body weight, 10.1111/j.1365-2516.2006.01332.x